IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock March 26, 2024 Read More »
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation March 20, 2024 Read More »
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024 March 20, 2024 Read More »
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline March 12, 2024 Read More »
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target February 23, 2024 Read More »
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s January 23, 2024 Read More »
IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial January 17, 2024 Read More »
